HIV-infected patients and treatment outcomes: an equivalence study of community-located, primary care-based HIV treatment vs. hospital-based specialty care in the Bronx, New York

被引:23
作者
Chu, C. [1 ]
Umanski, G. [1 ]
Blank, A. [1 ]
Grossberg, R. [2 ]
Selwyn, P. A. [1 ]
机构
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY 10467 USA
[2] Montefiore Med Ctr, Albert Einstein Coll Med, Div Infect Dis, Dept Med, Bronx, NY 10467 USA
来源
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV | 2010年 / 22卷 / 12期
基金
美国国家卫生研究院;
关键词
HIV primary care; community-based health services; HIV treatment outcomes; ACTIVE ANTIRETROVIRAL THERAPY; PHYSICIAN SPECIALIZATION; RISK-FACTORS; PREDICTORS; PREVALENCE; ZIDOVUDINE; LAMIVUDINE; FAILURE; SAMPLE; ACCESS;
D O I
10.1080/09540121.2010.484456
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The HIV-infected population in the USA is expanding as patients survive longer and new infections are identified. In many areas, particularly rural/medically underserved regions, there is a growing shortage of providers with sufficient HIV expertise. HIV services incorporated into community-based (CB), primary care settings may therefore improve the distribution and delivery of HIV treatment. Our objective was to describe/compare patients and treatment outcomes in two settings: a community-located, primary care-based HIV program, and a hospital-based (HB) specialty center. CB providers had on-site access to generalist HIV experts. The hospital center was staffed primarily by infectious disease physicians. This was a retrospective cohort study of 854 HIV-positive adults initiating care between 1/2005 and 12/2007 within an academic medical center network in the Bronx, NY. Treatment outcomes were virologic and immunologic response at 16-32 and 48 weeks, respectively, after combination antiretroviral therapy (cART) initiation. We found that HB subjects presented with a higher prevalence of AIDS (59% vs. 46%, p0.01) and lower initial CD4 (385 vs. 437, p0.05) than CB subjects. Among 178 community vs. 237 hospital subjects starting cART, 66% vs. 62% achieved virologic suppression (95% confidence interval (CI) difference -0.14-0.06) and 49% vs. 59% achieved immunologic success, defined as a 100 cell/mm3 increase in CD4 (95% CI difference 0.00-0.19). The multivariate-adjusted likelihoods of achieving viral suppression [OR=1.24 (95% CI 0.69-2.33)] and immunologic success [OR=0.76 (95% CI 0.47-1.21)] were not statistically significant for community vs. hospital subjects. Because this was an observational study, propensity scores were used to address potential selection bias when subjects presented to a particular setting. In conclusion, HIV-infected patients initiate care at CB clinics earlier and with less advanced HIV disease. Treatment outcomes are comparable to those at a HB specialty center, suggesting that HIV care can be delivered effectively in community settings.
引用
收藏
页码:1522 / 1529
页数:8
相关论文
共 22 条
[1]   Virologic success in an urban HIV clinic: outcome at 12 months in patients who were HAART naive [J].
Blanchard, Edward ;
Klibanov, Olga M. ;
Axelrod, Peter ;
Palermo, Brandon ;
Samuel, Rafik .
HIV CLINICAL TRIALS, 2008, 9 (03) :186-191
[2]  
Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1
[3]   Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study [J].
Brown, TT ;
Cole, SR ;
Li, XH ;
Kingsley, LA ;
Palella, FJ ;
Riddler, SA ;
Visscher, BR ;
Margolick, JB ;
Dobs, AS .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) :1179-1184
[4]  
Campsmith M. L., 2008, Morbidity and Mortality Weekly Report, V57, P1073
[5]  
Cohn SE, 2001, J ACQ IMMUN DEF SYND, V28, P385, DOI 10.1097/00126334-200112010-00013
[6]   HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy [J].
Deeks, SG ;
Hecht, FM ;
Swanson, M ;
Elbeik, T ;
Loftus, R ;
Cohen, PT ;
Grant, RM .
AIDS, 1999, 13 (06) :F35-F43
[7]   Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine - AIDS clinical trials group protocol 320 [J].
Demeter, LM ;
Hughes, MD ;
Coombs, RW ;
Jackson, JB ;
Grimes, JM ;
Bosch, RJ ;
Fiscus, SA ;
Spector, SA ;
Squires, KE ;
Fischl, MA ;
Hammer, SM .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (11) :954-964
[8]   Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001 [J].
Gebo, KA ;
Fleishman, JA ;
Conviser, R ;
Reilly, ED ;
Korthuis, PT ;
Moore, RD ;
Hellinger, J ;
Keiser, P ;
Rubin, HR ;
Crane, L ;
Hellinger, FJ ;
Mathews, WC .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (01) :96-103
[9]   Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study [J].
Glass, T. R. ;
Ungsedhapand, C. ;
Wolbers, M. ;
Weber, R. ;
Vernazza, P. L. ;
Rickenbach, M. ;
Furrer, H. ;
Bernasconi, E. ;
Cavassini, M. ;
Hirschel, B. ;
Battegay, M. ;
Bucher, H. C. .
HIV MEDICINE, 2006, 7 (06) :404-410
[10]   Impact of Patient Race on Patient Experiences of Access and Communication in HIV Care [J].
Korthuis, P. Todd ;
Saha, Somnath ;
Fleishman, John A. ;
McGrath, Moriah McSharry ;
Josephs, Joshua S. ;
Moore, Richard D. ;
Gebo, Kelly A. ;
Hellinger, James ;
Beach, Mary Catherine .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 (12) :2046-2052